• COVID
• ICU
• Superinfection

Our group evaluated in a retrospective way the incidence of superinfection in our COVID19-ICU, called "Bolla Covid"; we analyzed the etiology of superinfection, the site of infection, the number of patient who developed superinfection, the number of infection episodes, the correlation between infection episodes and outcomes: infection without sepsis, sepsis, septic shock (as defined by SSC/ESICM task force 2016); finally we evaluated mortality between the group who developed superinfection and the group who did not.
Results: we found an incidence of superinfection similar to that described in literature for ICU patients (55% of the court). We found a mild difference in mortality rates: 78% in the superinfection group versus 60% in the group who not developed superinfection. About etiology, Acinetobacter Baumannii MDR was the major cause of VAP and bacteremia; we found also a not insignificant incidence of Enterococcus spp driven bacteremias, as recently described in other papers.